Disclosures for "The MOXIe Trial of Omaveloxolone in Friedreich Ataxia: Exploring the Transient Nature of Treatment-emergent Adverse Events"
-
The institution of Dr. Lynch has received research support from reata. The institution of Dr. Lynch has received research support from PTC. Dr. Lynch has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Boesch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for VICO. Dr. Boesch has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for REATA.
-
The institution of Prof. Delatycki has received research support from MRFF. The institution of Prof. Delatycki has received research support from NHMRC. The institution of Prof. Delatycki has received research support from MRFF.
-
Paola Giunti has nothing to disclose.
-
Angie Goldsberry has received personal compensation for serving as an employee of Reata Pharmaceuticals.
-
Dr. Hoyle has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for National Football League. Dr. Hoyle has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Avexis. Dr. Hoyle has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Reata. The institution of Dr. Hoyle has received research support from REATA. The institution of Dr. Hoyle has received research support from TAKEDA.
-
Dr. Mathews has received personal compensation for serving as an employee of Avidity Bioscience. The institution of Dr. Mathews has received research support from NIH. The institution of Dr. Mathews has received research support from Centers for Disease Control and Prevention. The institution of Dr. Mathews has received research support from Muscular Dystrophy Association . The institution of Dr. Mathews has received research support from Friedreich's Ataxia Research Alliance . The institution of Dr. Mathews has received research support from Sarepta . The institution of Dr. Mathews has received research support from Pfizer. The institution of Dr. Mathews has received research support from Reata . The institution of Dr. Mathews has received research support from PTC Therapeutics, Inc. The institution of Dr. Mathews has received research support from Italfarmaco . The institution of Dr. Mathews has received research support from AMO. The institution of Dr. Mathews has received research support from FibroGen. The institution of Dr. Mathews has received research support from Capricor. The institution of Dr. Mathews has received research support from edgewise. The institution of Dr. Mathews has received research support from biogen.
-
Dr. Khan has nothing to disclose.
-
Colin Meyer has received personal compensation for serving as an employee of Reata Pharmaceuticals. Colin Meyer has stock in Reata Pharmaceuticals.
-
Dr. Murai has nothing to disclose.
-
Dr. Nachbauer has received personal compensation in the range of $0-$499 for serving as a Consultant for Reata. Dr. Nachbauer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Reata.
-
Dr. Perlman has nothing to disclose.
-
Dr. Subramony has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avidity. Dr. Subramony has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dyne. Dr. Subramony has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lupin. Dr. Subramony has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Fallonmedica. The institution of Dr. Subramony has received research support from Reata. The institution of Dr. Subramony has received research support from Retrotope. The institution of Dr. Subramony has received research support from Acceleron. The institution of Dr. Subramony has received research support from Biohaven. The institution of Dr. Subramony has received research support from Pharnext. The institution of Dr. Subramony has received research support from Fulcrum. The institution of Dr. Subramony has received research support from National Ataxia Foundation. The institution of Dr. Subramony has received research support from Friedreich Ataxia Research Alliance. The institution of Dr. Subramony has received research support from Muscular Dystrophy Association. The institution of Dr. Subramony has received research support from Univ of Rochester, MDA. The institution of Dr. Subramony has received research support from Virginia Commonwealth Univ (FDA, Wyck Foundation)). The institution of Dr. Subramony has received research support from Children's Hospital, Philadelphia (FDA). The institution of Dr. Subramony has received research support from Houston Methodist (NIH). The institution of Dr. Subramony has received research support from NIHR01 AR076060-01A1 . The institution of Dr. Subramony has received research support from NIH2R42HD089804-04 . The institution of Dr. Subramony has received research support from NIH R01 AR056973 . The institution of Dr. Subramony has received research support from FSHD Society. The institution of Dr. Subramony has received research support from AAVANTI BIO. The institution of Dr. Subramony has received research support from COHAV FL State Dept of Health.
-
Dr. Zesiewicz has received personal compensation for serving as an employee of Medscape. Dr. Zesiewicz has received intellectual property interests from a discovery or technology relating to health care.